ArticleFrontiers in cellular and infection microbiology2025
A model for predicting bacteremia species based on host immune response.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Introduction: Clinicians encounter significant challenges in quickly and accurately identifying the bacterial species responsible for patient bacteremia and in selecting appropriate antibiotics for timely treatment. This study introduces a novel approach that combines immune response data from routine blood counts with assessments of immune cell activation, specifically through quantitative measurements of Rho family GTPase activity. The combined data were used to develop a machine-learning model capable of distinguishing specific classes of bacteria and their associations. Methods: We aimed to determine whether different classes of bacteria elicit distinct patterns of host immune responses, as indicated by quantitative differences in leukocyte populations from routine complete blood counts with differential. Concurrently, we conducted quantitative measurements of activated Rac1 (Rac1•GTP) levels using a novel 'G-Trap assay' we developed. With the G-Trap, we measured Rac1•GTP in peripheral blood monocytes (PBMC) and polymorphonuclear (PMN) cells from blood samples collected from 28 culture-positive patients and over 80 non-infected patients used as controls. Results: Our findings indicated that 18 of the 28 patients with bacteremia showed an increase of ≥ 3-fold in Rac1•GTP levels compared to the controls. The remaining ten patients with bacteremia exhibited either neutrophilia or pancytopenia and displayed normal to below-normal Rac1 GTPase activity, which is consistent with bacteria-induced immunosuppression. To analyze the data, we employed partial least squares discriminant analysis (PLS-DA), a supervised method that optimizes group separation and aids in building a novel machine-learning model for pathogen identification. Discussion: The results demonstrated that PLS-DA effectively differentiates between specific pathogen groups, and external validation confirmed the predictive model's utility. Given that bacterial culture confirmation may take several days, our study underscores the potential of combining routine assays with a machine-learning model as a valuable clinical decision-support tool. This approach could enable prompt and accurate treatment on the same day that patients present to the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.